Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Junzo HamanishiIkuo Konishi

Abstract

Programmed death-1 (PD-1), a coinhibitory immune signal receptor expressed in T cells, binds to PD-1 ligand and regulates antitumor immunity. Nivolumab is an anti-PD-1 antibody that blocks PD-1 signaling. We assessed the safety and antitumor activity of nivolumab in patients with platinum-resistant ovarian cancer. Twenty patients with platinum-resistant ovarian cancer were treated with an intravenous infusion of nivolumab every 2 weeks at a dose of 1 or 3 mg/kg (constituting two 10-patient cohorts) from October 21, 2011. This phase II trial defined the primary end point as the best overall response. Patients received up to six cycles (four doses per cycle) of nivolumab treatment or received doses until disease progression occurred. Twenty nivolumab-treated patients were evaluated at the end of the trial on December 7, 2014. Grade 3 or 4 treatment-related adverse events occurred in eight (40%) of 20 patients. Two patients had severe adverse events. In the 20 patients in whom responses could be evaluated, the best overall response was 15%, which included two patients who had a durable complete response (in the 3-mg/kg cohort). The disease control rate in all 20 patients was 45%. The median progression-free survival time was 3.5 m...Continue Reading

References

Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Jan 17, 2003·The New England Journal of Medicine·Lin ZhangGeorge Coukos
Dec 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·R Houston ThompsonEugene D Kwon
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kristin K ZornMichael J Birrer
Feb 13, 2007·Gynecologic Oncology·David R CrotzerDavid M Gershenson
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G MutchAngeles Alvarez Secord
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen A CannistraWilliam McGuire
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
May 27, 2008·Nature Reviews. Immunology·Weiping Zou, Lieping Chen
Aug 14, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard W TothillDavid D L Bowtell
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Nov 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lana E KandalaftGeorge Coukos
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Aug 5, 2011·Drugs·R Wendel Naumann, Robert L Coleman
Oct 1, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Junzo HamanishiIkuo Konishi
Nov 2, 2011·Gynecologic Oncology·Wei-Ting HwangGeorge Coukos
Dec 24, 2011·Nature·Ira MellmanGlenn Dranoff
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Jan 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kaoru AbikoIkuo Konishi
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Oct 22, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Robert J MorganUNKNOWN National comprehensive cancer networks
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders

❮ Previous
Next ❯

Citations

Jan 19, 2016·Future Oncology·Hampig Raphael KourieAhmad Hussein Awada
Nov 19, 2015·Expert Review of Anticancer Therapy·Jose C Villasboas, Stephen M Ansell
Jan 30, 2016·Expert Review of Clinical Immunology·Gulden MenderesAlessandro D Santin
Jan 26, 2016·Immunotherapy·David AllardJohn Stagg
Jan 20, 2016·Bulletin du cancer·Nicolas MagnéStéphane Vignot
Jan 1, 2016·Nature Reviews. Clinical Oncology·Robert L Coleman
Jan 7, 2016·Nature Medicine·Christopher A KlebanoffNicholas P Restifo
Aug 27, 2015·Human Vaccines & Immunotherapeutics·Rikke AndersenInge Marie Svane
Mar 13, 2016·International Journal of Clinical Oncology·Masaki MandaiIkuo Konishi
Mar 31, 2016·Cytokine & Growth Factor Reviews·Daniel S GreenKathryn C Zoon
Feb 27, 2016·Expert Opinion on Pharmacotherapy·Victor Rodriguez-FreixinosAmit M Oza
Mar 27, 2016·Gynecologic Oncology·Dmitriy Zamarin, Amir A Jazaeri
Mar 5, 2016·Expert Review of Anticancer Therapy·Jennifer McLachlanSusana Banerjee
Apr 5, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V R BelumM E Lacouture
Apr 7, 2016·Critical Reviews in Oncology/hematology·Hampig Raphael KourieAhmad Hussein Awada
Apr 9, 2016·International Immunology·Junzo HamanishiIkuo Konishi
May 4, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CoukosL E Kandalaft
May 4, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A K L ReynersM Jalving
May 5, 2016·Nature Reviews. Clinical Oncology·Celine BoutrosCaroline Robert
May 18, 2016·Journal of Ovarian Research·Gloria MitticaGiorgio Valabrega
May 14, 2016·Gynecologic Oncology·Taylor B TurnerRebecca C Arend
Jul 19, 2016·Memo·Lukas WeissRichard Greil
Jun 1, 2016·Gynecologic Oncology·John B Liao
May 3, 2016·Human Vaccines & Immunotherapeutics·Arun RajanJames L Gulley
Jun 21, 2016·Journal de gynécologie, obstétrique et biologie de la reproduction·M NayamaD Vinatier
Aug 26, 2016·Nature Reviews. Disease Primers·Ursula A MatulonisBeth Y Karlan
May 3, 2015·Best Practice & Research. Clinical Obstetrics & Gynaecology·Pratibha S BinderDavid G Mutch
Sep 30, 2016·Frontiers in Immunology·Mariella Della ChiesaEmanuela Marcenaro
Sep 17, 2016·Journal of Translational Medicine·Anselmo PapaFederica Tomao
Oct 18, 2016·Cancer Medicine·Nageatte IbrahimF Stephen Hodi
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Stefani SprangerThomas F Gajewski
Nov 5, 2016·International Journal of Cancer. Journal International Du Cancer·Yan TieHeng Zheng
Dec 17, 2016·International Journal of Molecular Sciences·Veronica RojasLorna Rodriguez-Rodriguez
Nov 4, 2016·Human Vaccines & Immunotherapeutics·Robert O Dillman
Jan 7, 2017·Nature Reviews. Drug Discovery·W Joost LesterhuisRichard A Lake
Dec 4, 2016·International Journal of Cancer. Journal International Du Cancer·Corinne A Levingston, M Rita I Young
Feb 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinDon S Dizon
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krisztian Homicsko, George Coukos
Mar 10, 2017·Expert Review of Anticancer Therapy·Philip JessmonPallavi Patwardhan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved